Midostaurin Drugs segmentation by application isolates three therapeutic indications: Acute Myeloid Leukemia (AML), Systemic Mastocytosis (SM), and Other hematologic malignancies. AML, specifically FLT3‑mutated disease, dominates the market, representing approximately 60 % of total sales. Its prominence stems from robust clinical efficacy data, guideline endorsement, and a sizable patient pool in both frontline and relapsed settings. Systemic Mastocytosis, approved for adult patients with advanced disease, contributes about 30 % of revenue; despite a smaller prevalence, the indication commands premium pricing due to limited therapeutic alternatives and a high unmet‑need profile. The residual 10 % originates from off‑label or investigational uses in rarer hematologic disorders, where midostaurin is evaluated in combination regimens or early‑phase trials. These application sub‑segments collectively shape the market’s revenue distribution, with AML driving volume, SM delivering higher margin contribution, and ancillary uses providing a modest but strategic foothold for future expansion. The chart below visualizes this application‑focused market taxonomy.
